BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCommercial

The listing on one of the world's largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex's primary digital treasury asset

Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction...

Related news

ENLVEnlivex Therapeutics2026-06-24 13:00 EST

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IBRXImmunityBio2026-08-10 13:00 EST

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

CADLCandel Therapeutics2026-06-25 12:05 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

BCTXBriaCell2026-07-07 11:30 EST

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

PHARPharming Group2026-08-13 05:00 EST

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

CUECue Biopharma Inc2026-06-02 20:05 EST

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

IBRXImmunityBio2026-06-01 17:51 EST

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

BCTXBriaCell2026-06-25 11:30 EST

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States